FDA Approves Selpercatinib for Medullary Thyroid Cancer with a RET Mutation

Why It Matters

Full approval cements selpercatinib as a standard‑of‑care option for RET‑mutant MTC, expanding access to a more effective and better‑tolerated therapy, especially for pediatric patients.

Key Takeaways

• FDA grants full approval for selpercatinib in RET‑mutant MTC
• Median progression‑free survival not reached, versus 16.8 months for comparators
• Hazard ratio 0.28 indicates 72% risk reduction versus standard TKIs
• Pediatric dosing approved for patients as young as 2 years

Pulse Analysis

Medullary thyroid cancer, though rare, poses a significant clinical challenge because it often harbors activating RET mutations that drive aggressive tumor growth. Before selpercatinib, clinicians relied on multi‑kinase inhibitors such as cabozantinib and vandetanib, which offered modest disease control but were plagued by high toxicity. The FDA’s traditional approval marks the first time a highly selective RET inhibitor has cleared the full regulatory hurdle for both adult and pediatric populations, reflecting a broader shift toward genotype‑driven oncology therapies.

The LIBRETTO‑531 trial, a randomized open‑label study, compared selpercatinib directly against physician‑chosen standard TKIs. Patients receiving selpercatinib experienced a median progression‑free survival that was not reached at the time of analysis, dramatically outpacing the 16.8‑month median of the control arm. The hazard ratio of 0.28 translates to a 72% reduction in the risk of disease progression or death, a statistically robust outcome (p<0.0001). Moreover, patient‑reported outcomes indicated fewer severe side‑effect burdens, and the safety profile was dominated by manageable events such as hypertension and fatigue, positioning selpercatinib as a more tolerable alternative.

From a market perspective, this approval expands Eli Lilly’s oncology portfolio and intensifies competition among targeted therapies for thyroid cancers. The inclusion of a pediatric indication—down to two years of age—opens a new revenue stream while addressing an unmet need for younger patients who previously faced limited options. Payers are likely to favor selpercatinib given its superior efficacy and quality‑of‑life benefits, potentially reshaping treatment algorithms and prompting insurers to renegotiate pricing for older multi‑kinase inhibitors. As real‑world data accumulate, the drug could also serve as a platform for combination studies aimed at overcoming resistance mechanisms, further solidifying its role in precision oncology.